Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Codex infant formula revision deferral to be urged by U.S., FDAer reports.

This article was originally published in The Tan Sheet

Executive Summary

CODEX INFANT FORMULA REVISION DEFERRAL TO BE URGED BY U.S. DELEGATES until the Federation of American Societies for Experimental Biology (FASEB) completes its review of infant formula nutrient requirements, Robert Moore, PhD, Center for Food Safety & Applied Nutrition senior regulatory scientist, told food and supplement industry representatives at an August 16 briefing held in Washington, D.C. Infant formula standards and other nutrition-related topics are slated to be discussed at the upcoming Oct. 7-11 meeting of the Codex Committee on Nutrition and Food for Special Dietary Uses in Bonn-Bad Godesberg, Germany.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel